Xvivo Perfusion AB (publ) (XVIPF) Stock Price & Analysis
Xvivo Perfusion AB (publ) (XVIPF) — price $21.80 (-4.60%), as of the Oct 2, 2026 trading session; market cap $687M.
Educational signal · not a buy or sell recommendation · How to read this
Xvivo Perfusion AB (publ) · XVIPF
Xvivo Perfusion AB (publ) is a medical technology company specializing in organ preservation and perfusion solutions for transplantation. With a focus on innovative products for ex-vivo lung perfusion, the company operates in a growing market driven by increasing demand for transplantable organs.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $21.80 | |
| Change on the day | -4.60% | |
| 52-week range | $16.98 – $30.95 | |
| Market capitalisation | $687M | |
| Price / earnings (trailing) | 76.01 | |
| Shares traded on the day | 592 |
Price & events
Other perspectives
Council score for Xvivo Perfusion AB (publ) (XVIPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the XVIPF film — every key number, told as a short cinematic story
~2 min · open the film
What is Xvivo Perfusion AB (publ) (XVIPF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xvivo Perfusion AB (publ) (XVIPF) is the company analyzed here. It employs 210 people and is led by Christoffer Rosenblad. In Q2 FY2026 it reported revenue of $23M and net income of $2M. The market values it at $687M.
What do the latest results show for Xvivo Perfusion AB (publ) (XVIPF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $23M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $23M | $2M | $0.05 (diluted) |
| Q1 FY2026 | $24M | $4M | $0.11 (diluted) |
| Q4 FY2025 | $22M | $3M | $0.10 (diluted) |
| Q3 FY2025 | $19M | $427,458.085 | $0.01 (diluted) |
What are the financial strengths and risks for Xvivo Perfusion AB (publ) (XVIPF)?
Short answer
The distress and quality screens read Piotroski F 5. Trailing ratios: ROE 4.1% · ROA 3.5% · current ratio 3.86 · earnings yield 1.3% · free-cash-flow yield 2.8%.
What has been published about Xvivo Perfusion AB (publ) (XVIPF)?
Xvivo Perfusion AB (publ) Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the XVIPF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is XVIPF a good stock to buy?
Stock Expert AI does not rate XVIPF buy, sell or hold. Xvivo Perfusion AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XVIPF stock price today?
The last price recorded on this page for Xvivo Perfusion AB (publ) (XVIPF) is $21.80, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What revenue streams does Xvivo Perfusion AB (publ) have in healthcare?
Xvivo Perfusion AB (publ) generates revenue primarily through the sale of its innovative medical devices and solutions for organ preservation and perfusion. Key products include the XVIVO System, STEEN Solution, and various disposable products tailored for transplantation needs.
What are the key factors to evaluate for XVIPF?
Evaluate XVIPF on fundamentals, analyst consensus, and risk factors. P/E: 76.01x. Not financial advice.
How frequently does XVIPF data refresh on this page?
XVIPF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XVIPF's recent stock price performance?
Xvivo Perfusion AB (publ) (XVIPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings that address critical needs in organ transplantation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XVIPF overvalued or undervalued right now?
Xvivo Perfusion AB (publ) (XVIPF) trades at 76.01x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XVIPF before investing?
Before investing in Xvivo Perfusion AB (publ) (XVIPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $21.80 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:14:29.134Z. | |
px.change | Change on the day | -4.60% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $687M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T17:14:28.016Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$1.05 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 76.01 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 592 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $23M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $16.98 – $30.95 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
id.employees | Employees | 210 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
id.ceo | Chief executive | Christoffer Rosenblad | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 4.1% · ROA 3.5% · current ratio 3.86 · earnings yield 1.3% · free-cash-flow yield 2.8% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.